Yu-Chen Hsu1, Ching-Yao Chen2, Ka-Wai Tam3,4,5, Chin-Yu Hsu6. 1. Division of Colon and Rectal Surgery, Department of Surgery, En Chu Kong Hospital, New Taipei City, Taiwan. 2. Department of Pharmacy, En Chu Kong Hospital, 399 Fuxing Road Sanxis District, New Taipei City, 23741, Taiwan. 3. Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. 4. Division of General Surgery, Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. 5. Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan. 6. Department of Pharmacy, En Chu Kong Hospital, 399 Fuxing Road Sanxis District, New Taipei City, 23741, Taiwan. hsujinyu@gmail.com.
Abstract
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) commonly occurs after chemotherapy, adversely affecting patients' quality of life. Recently, studies have shown inconsistent antiemetic effects of two common 5-hydroxytryptamine 3 receptor antagonists, namely, palonosetron and granisetron. Therefore, we conducted a meta-analysis to evaluate the effectiveness of palonosetron versus granisetron in preventing CINV. METHODS: Relevant studies were obtained from PubMed, Embase, and Cochrane databases. The primary outcome was the complete response (CR) rate. Secondary outcomes were headache and constipation events. RESULTS: In total, 12 randomized controlled trials and five retrospective studies were reviewed. Palonosetron was consistently statistically superior to granisetron in all phases in terms of the CR rate (acute phases: odds ratio [OR] = 1.28, 95% confidence interval [CI] = 1.06-1.54; delayed phases: OR = 1.38, 95% CI = 1.13-1.69; and overall phases: OR = 1.37, 95% CI = 1.17-1.60). Moreover, a non-significant difference was found between the two groups in terms of the headache event, but the occurrence of the constipation event was lower in the granisetron group than in the palonosetron group. CONCLUSION: Palonosetron showed a higher protective efficacy in all phases of CINV prevention, especially in delayed phases, and no relatively severe adverse effects were observed.
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) commonly occurs after chemotherapy, adversely affecting patients' quality of life. Recently, studies have shown inconsistent antiemetic effects of two common 5-hydroxytryptamine 3 receptor antagonists, namely, palonosetron and granisetron. Therefore, we conducted a meta-analysis to evaluate the effectiveness of palonosetron versus granisetron in preventing CINV. METHODS: Relevant studies were obtained from PubMed, Embase, and Cochrane databases. The primary outcome was the complete response (CR) rate. Secondary outcomes were headache and constipation events. RESULTS: In total, 12 randomized controlled trials and five retrospective studies were reviewed. Palonosetron was consistently statistically superior to granisetron in all phases in terms of the CR rate (acute phases: odds ratio [OR] = 1.28, 95% confidence interval [CI] = 1.06-1.54; delayed phases: OR = 1.38, 95% CI = 1.13-1.69; and overall phases: OR = 1.37, 95% CI = 1.17-1.60). Moreover, a non-significant difference was found between the two groups in terms of the headache event, but the occurrence of the constipation event was lower in the granisetron group than in the palonosetron group. CONCLUSION: Palonosetron showed a higher protective efficacy in all phases of CINV prevention, especially in delayed phases, and no relatively severe adverse effects were observed.
Authors: Paul J Hesketh; Mark G Kris; Ethan Basch; Kari Bohlke; Sally Y Barbour; Rebecca Anne Clark-Snow; Michael A Danso; Kristopher Dennis; L Lee Dupuis; Stacie B Dusetzina; Cathy Eng; Petra C Feyer; Karin Jordan; Kimberly Noonan; Dee Sparacio; Mark R Somerfield; Gary H Lyman Journal: J Clin Oncol Date: 2017-07-31 Impact factor: 44.544
Authors: M S Aapro; S M Grunberg; G M Manikhas; G Olivares; T Suarez; S A Tjulandin; L F Bertoli; F Yunus; B Morrica; F Lordick; A Macciocchi Journal: Ann Oncol Date: 2006-06-09 Impact factor: 32.976
Authors: Tobias Engel Ayer Botrel; Otávio Augusto C Clark; Luciana Clark; Luciano Paladini; Enéas Faleiros; Bruna Pegoretti Journal: Support Care Cancer Date: 2010-05-22 Impact factor: 3.603
Authors: Marko Popovic; David G Warr; Carlo Deangelis; May Tsao; Kelvin K W Chan; Michael Poon; Cheryl Yip; Natalie Pulenzas; Henry Lam; Liying Zhang; Edward Chow Journal: Support Care Cancer Date: 2014-03-04 Impact factor: 3.603
Authors: Maurice J D L van der Vorst; Elisabeth C W Neefjes; Inge R H M Konings; Henk M W Verheul Journal: Support Care Cancer Date: 2015-06-04 Impact factor: 3.603
Authors: Peter M Anderson; Stefanie M Thomas; Shauna Sartoski; Jacob G Scott; Kaitlin Sobilo; Sara Bewley; Laura K Salvador; Maritza Salazar-Abshire Journal: Nutrients Date: 2021-12-08 Impact factor: 5.717